Codrituzumab  (Synonyms: GC33; RO5137382)

Codrituzumab (GC33) is a humanized monoclonal antibody targeting human GPC3 (glypican-3), with high affinity (K_d of 0.673 nM). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth^[1][2][3][4].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

GPC3

Codrituzumab (once-weekly for 21 days) combined with PD-L1 mAb demonstrates a marked antitumor effect, enhancing tumor infiltration of PD-L1-positive immune cells, such as macrophages and multinucleated giant cells in the Hepa1-6/hGPC3 mice model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2719  [NCBI]

P51654

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

145.58 kDa

1365267-33-9

Liquid

Colorless to light yellow

[Codrituzumab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized Glypican-3/GPC3 Protein, Human (HEK293, His, HY-P70487) can bind Codrituzumab. The EC₅₀ for this effect is 13.3 ng/mL.
• 
  Flow cytometric analysis of 1X10⁶ Jurkat cells with Codrituzumab (HY-P99013, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Mika Endo, et al. Abstract 2747: Anti-glypican-3 monoclonal antibody (codrituzumab/GC33/RO5137382) treatment enhances tumor infiltration of PD-L1-positive macrophages, and combination therapy with anti-PD-L1 monoclonal antibody promotes antitumor effects. Cancer Res (2018) 78 (13_Supplement): 2747.

  [2]. Chen G, et al. Combining expression of GPC3 in tumors and CD16 on NK cells from peripheral blood to identify patients responding to codrituzumab. Oncotarget. 2018 Jan 2;9(12):10436-10444.  [Content Brief]

  [3]. Carrasquillo JA, et al. I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma. EJNMMI Res. 2018 Mar 5;8(1):20.  [Content Brief]

  [4]. Abou-Alfa GK, et al. Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma. J Hepatol. 2016 Aug;65(2):289-95.  [Content Brief]